ThoRAciC Trauma IntubatiON Risk Score for Blunt Trauma
Launched by AZIENDA USL DI BOLOGNA · Nov 25, 2022
Trial Information
Current as of January 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the ThoRAciC Trauma IntubatiON Risk Score for Blunt Trauma, is studying the factors that might help predict whether patients with blunt chest injuries need to be intubated (a procedure where a tube is placed in the throat to help with breathing). The goal is to develop a scoring system based on various medical tests and observations made within the first six hours after a patient arrives at the hospital. This can help doctors make more informed decisions about treatment.
To be eligible for this study, participants need to be at least 18 years old and have sustained blunt chest trauma with a significant injury. They should also have a Glasgow Coma Scale (GCS) score above 8 when they arrive at the emergency department and have a full-body CT scan done within six hours of arrival. However, individuals with certain conditions, such as those who are under 18 years old, have severe brain injuries, or have already been intubated, are not eligible to participate. If someone joins the study, they will undergo regular assessments and tests that will help researchers gather important data on their condition and treatment needs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Blunt thoracic trauma with a documentable lesion (T-AIS ≥ 2)
- • Age ≥ 18 years
- • GCS \> 8 at ED admission
- • Total body CT scan available performed within 6 hours from ED admission
- Exclusion Criteria:
- • - Penetrating thoracic trauma
- • Age \< 18 years
- • GCS \<= 8 at ED admission
- • Patients already intubated at ED arrival
- • Do not intubate order, for any reason
- • Intubation for Urgent/Emergent surgery within 24 hours from hospital arrival
About Azienda Usl Di Bologna
Azienda USL di Bologna is a prominent public healthcare organization based in Bologna, Italy, dedicated to providing high-quality medical services and advancing public health initiatives. As a clinical trial sponsor, it plays a critical role in facilitating innovative research that enhances patient care and supports the development of new therapeutic interventions. The organization collaborates with a network of healthcare professionals, academic institutions, and industry partners to conduct rigorous clinical studies, ensuring adherence to ethical standards and regulatory requirements. With a commitment to improving healthcare outcomes, Azienda USL di Bologna actively contributes to the generation of evidence-based practices in the medical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials